LPCN News and Press, Lipocine Inc. From 05/06/21

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021 PR Newswire SALT LAKE CITY , May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, to...

April is Getting Off to a Great Start For These 5 Biotech Stocks With only six days behind us in April so far, biotech penny stocks continue to lead the charge. Since they’re so cheap (stocks under $5, by definition), traders are on the hunt for the next breakout name. The obviou...

Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals (INFI) +13%.Losers: Translate Bio (TBIO) -32%, ContraFect (CFRX) -13%, Lipocine (LPCN...

Translate Bio (TBIO) -26% after Translate Bio’s Cystic Fibrosis therapy fails to improve lung function in Phase 1/2 trial.PhaseBio Pharmaceuticals (PHAS) -14% on equity raise.Broadway Financial (BYFC) -13% after stockholders of Broadway Financial and CFBan...

Gainers: Takung Art (TKAT) +122%.Zhongchao (ZCMD) +52%.Oriental Culture (OCG) +43%.Integrated Media Technology (IMTE) +43%.Immatics (IMTX) +33%.Puyi (PUYI) +29%.Willis Lease Finance (WLFC) +24%.Lipocine (LPCN) +24%.Liquid Media (YVR) +21%.Sigma Labs (SGLB) +20%.Losers: Sun...

Gainers: Zhongchao (ZCMD) +53%, Immatics (IMTX) +42%, Lipocine (LPCN) +23%, FSD Pharma (HUGE) +18%, Nabriva Therapeutics (NBRV) +18%.Losers: SunLink Health Systems (SSY) -28%, Rubius Therapeutics (RUBY) -17%, CHF Solutions CHFS&...

Lipocine Announces Financial Results For The Year Ended December 31, 2020 PR Newswire SALT LAKE CITY , March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today...

Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference PR Newswire SALT LAKE CITY , March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine dis...

Lipocine (LPCN) shares rise nearly 6% premarket after announcing the publication of preclinical results supporting the therapeutic potential of LPCN 1144 in the treatment of and non-alcoholic steatohepatitis ("NASH") and hepatic fibrosis.The results were featured in a pape...

Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis PR Newswire SALT LAKE CITY , March 4, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinic...